Kramar A - Search Results

1

Continual reassessment methods in phase I trials of the combination of two drugs in oncology.

Kramar A, Lebecq A, Candalh E. Kramar A, et al. Stat Med. 1999 Jul 30;18(14):1849-64. doi: 10.1002/(sici)1097-0258(19990730)18:14<1849::aid-sim222>3.0.co;2-i. Stat Med. 1999. PMID: 10407256

2

A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.

Paoletti X, Kramar A. Paoletti X, et al. Among authors: kramar a. Stat Med. 2009 Oct 30;28(24):3012-28. doi: 10.1002/sim.3682. Stat Med. 2009. PMID: 19672839

3

Two-treatment comparison based on joint toxicity and efficacy ordered alternatives in cancer trials.

Letierce A, Tubert-Bitter P, Kramar A, Maccario J. Letierce A, et al. Among authors: kramar a. Stat Med. 2003 Mar 30;22(6):859-68. doi: 10.1002/sim.1446. Stat Med. 2003. PMID: 12627405

4

np1: a computer program for dose escalation strategies in phase I clinical trials.

Kramar A, Houédé N, Paoletti X. Kramar A, et al. Comput Methods Programs Biomed. 2007 Oct;88(1):8-17. doi: 10.1016/j.cmpb.2007.06.006. Epub 2007 Aug 24. Comput Methods Programs Biomed. 2007. PMID: 17719124

5

Two-part statistics with paired data.

Bascoul-Mollevi C, Gourgou-Bourgade S, Kramar A. Bascoul-Mollevi C, et al. Among authors: kramar a. Stat Med. 2005 May 15;24(9):1435-48. doi: 10.1002/sim.1979. Stat Med. 2005. PMID: 15565738

6

[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB].

Ezzalfani M, Dugué A, Mollevi C, Pulido M, Bonnetain F, Filleron T, Gal J, Gauthier M, Le Deley MC, Le Tourneau C, Médioni J, Nguyen JM, Chabaud S, Teixeira L, Thivat E, You B, Kramar A, Paoletti X. Ezzalfani M, et al. Among authors: kramar a. Bull Cancer. 2015 Jan;102(1):73-82. doi: 10.1016/j.bulcan.2014.10.001. Epub 2015 Jan 2. Bull Cancer. 2015. PMID: 25609488 Review. French.

7

Early stopping rules in clinical trials based on sequential monitoring of serious adverse events.

Kramar A, Bascoul-Mollevi C. Kramar A, et al. Med Decis Making. 2009 May-Jun;29(3):343-50. doi: 10.1177/0272989X08327332. Epub 2008 Dec 10. Med Decis Making. 2009. PMID: 19073996

8

Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.

Jacot W, Bibeau F, Gourgou-Bourgade S, Gutowski M, Colombo PE, Bleuse JP, Kramar A, Romieu G. Jacot W, et al. Among authors: kramar a. Am J Clin Oncol. 2010 Dec;33(6):544-9. doi: 10.1097/COC.0b013e3181bead47. Am J Clin Oncol. 2010. PMID: 20042972 Clinical Trial.

9

Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.

Ychou M, Duffour J, Kramar A, Debrigode C, Gourgou S, Bressolle F, Pinguet F. Ychou M, et al. Among authors: kramar a. Cancer Chemother Pharmacol. 2003 Oct;52(4):282-90. doi: 10.1007/s00280-003-0658-0. Epub 2003 Jun 19. Cancer Chemother Pharmacol. 2003. PMID: 12827293 Clinical Trial.

10

A nonparametric comparison of the effectiveness of treatments: a multivariate toxicity-penalized approach.

Tubert-Bitter P, Letierce A, Bloch DA, Kramar A. Tubert-Bitter P, et al. Among authors: kramar a. J Biopharm Stat. 2005;15(1):129-42. doi: 10.1081/bip-200040851. J Biopharm Stat. 2005. PMID: 15702609

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters